Stay updated with breaking news from Peter Greenleaf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aurinia Pharmaceuticals Inc. today announced that the National Institute for Health and Care Excellence has recommended LUPKYNIS® as an option for treating adults with active lupus nephritis ... | May 3, 2023
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS (voclosporin) as an option
03.05.2023 - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS (voclosporin) as an option for treating adults with active lupus ... Seite 1
Aurinia Pharmaceuticals Inc. today announced that the Swiss Agency for Therapeutic Products has granted marketing authorization of LUPKYNIS® in combination with a background immunosuppressive... | May 2, 2023
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) has been assigned an average rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month […]